Who we are
We develop and manufacture lentiviral vectors as a European leader working under both EMA and FDA standards. The lentiviral vectors produced by VIVEbiotech are administered both ex-vivo and in-vivo to treat a range of disorders, including haematological and solid cancers, and rare diseases.
We are a Contract Development and Manufacturing Organization (CDMO) with over 40 biotech companies worldwide that have placed their trust in us.
A solid project with its own personality
Our roots are 100% Guipuzcoan. Since 2015 we have spearheaded the creation of an ecosystem in our region specialized in health-related biotechnology aimed at personalized precision medicine.
Our stable international clients and large-scale projects allow us to consolidate our structure and continue to grow sustainably, positioning our company and our region at the forefront of the medicine of the future on a global level.
2015 - Today
![](https://www.vivebiotech.com/wp-content/themes/vivebiotech/dist/images/capside_7f107151.png)
US, European, Asian and Australian customers
Compliance with EMA and FDA regulations
Expansion plan completed in 2021
One of the few companies fully focused on lentiviral vectors
Timely slot availability